XenoTech Adds In Vitro Toxicology to Its Drug Development Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The company is launching the ECVAM validated skin irritation screening assay (OECD TG 439) immediately, with additional screens for skin sensitization, ocular irritation and other organotypic models beginning this fall (2015) and future platforms expanding into endocrine disruption, genetox and hepatotoxicity.
XenoTech has appointed Colleen Toole, Ph.D., as the Principal Scientist of its newly created in vitro toxicology group. Colleen will oversee all operations of the new department and will be instrumental in the continued development of XenoTech’s in vitro toxicology services. Colleen has a strong knowledge of predictive in vitro toxicology models to identify new drug candidates, chemicals, cosmetics, and consumer products that present a low risk for toxicity.“The formation of our new in vitro toxicology department shows XenoTech’s commitment to expanding into complementing areas around our extensive ADME - DMPK expertise to better predict in vivo outcomes through in vitro systems,” said XenoTech COO Jason Neat.
